Company intelligence / Profile preview

Shanghai Microdom Biotech

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Shanghai Microdom Biotech provides pilot-scale process development and manufacturing for clinical samples of vaccines and protein biologics. Its parent company, Reinovax, has advanced a 24-valent pneumococcal conjugate vaccine through completed phase II trials in adults and expects to start phase III trials in 2025. The company supports production for phase I–III clinical trials, with GMP-like capabilities and involvement in innovative vaccine development.

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteinPolysaccharideVaccineProtein
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Shanghai Microdom Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Microdom Biotech.

Explore the full profile